Patents by Inventor Kaname Kimura
Kaname Kimura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11787877Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.Type: GrantFiled: December 22, 2020Date of Patent: October 17, 2023Assignees: RIKEN, KYOWA KIRIN CO., LTD.Inventors: Kensaku Sakamoto, Kazumasa Ohtake, Yoshimi Yamaguchi, Shigeyuki Yokoyama, Tatsuo Yanagisawa, Akiko Matsumoto, Akifumi Kato, Yasuhisa Shiraishi, Kaname Kimura, Masakazu Homma
-
Publication number: 20210107997Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.Type: ApplicationFiled: December 22, 2020Publication date: April 15, 2021Applicants: RIKEN, KYOWA KIRIN CO., LTD.Inventors: Kensaku Sakamoto, Kazumasa Ohtake, Yoshimi Yamaguchi, Shigeyuki Yokoyama, Tatsuo Yanagisawa, Akiko Matsumoto, Akifumi Kato, Yasuhisa Shiraishi, Kaname Kimura, Masakazu Homma
-
Patent number: 10906990Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.Type: GrantFiled: August 18, 2016Date of Patent: February 2, 2021Assignees: RIKEN, KYOWA KIRIN CO., LTD.Inventors: Kensaku Sakamoto, Kazumasa Ohtake, Yoshimi Yamaguchi, Shigeyuki Yokoyama, Tatsuo Yanagisawa, Akiko Matsumoto, Akifumi Kato, Yasuhisa Shiraishi, Kaname Kimura, Masakazu Homma
-
Patent number: 10561727Abstract: The present invention relates to an antibody specifically binding to human growth arrest specific 6 (hGas6). Specifically, the present invention relates to a monoclonal antibody or an antibody fragment thereof which binds to at least one of amino acid residues at positions 314, 315, and 316 of human Gas6, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment, a transformed cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment, a reagent for detection or assay of Gas6, comprising the antibody or the antibody fragment, a therapeutic agent or a diagnostic agent for a Gas6-related disease, comprising the antibody or the antibody fragment as an active ingredient, and use of the antibody or the antibody fragment for the production of a therapeutic agent or a diagnostic agent for a Gas6-related disease.Type: GrantFiled: October 20, 2015Date of Patent: February 18, 2020Assignee: Kyowa Kirin Co., Ltd.Inventors: Yuko Ube, Tsuyoshi Yamada, Yuji Yamazaki, Kaname Kimura, Akiko Hariguchi, Shinya Ogawa
-
Publication number: 20190127488Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.Type: ApplicationFiled: August 18, 2016Publication date: May 2, 2019Applicants: RIKEN, KYOWA HAKKO KIRIN CO., LTD.Inventors: Kensaku SAKAMOTO, Kazumasa OHTAKE, Yoshimi YAMAGUCHI, Shigeyuki YOKOYAMA, Tatsuo YANAGISAWA, Akiko MATSUMOTO, Akifumi KATO, Yasuhisa SHIRAISHI, Kaname KIMURA, Masakazu HOMMA
-
Publication number: 20180339041Abstract: The present invention relates to an antibody specifically binding to human growth arrest specific 6 (hGas6). Specifically, the present invention relates to a monoclonal antibody or an antibody fragment thereof which binds to at least one of amino acid residues at positions 314, 315, and 316 of human Gas6, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment, a transformed cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment, a reagent for detection or assay of Gas6, comprising the antibody or the antibody fragment, a therapeutic agent or a diagnostic agent for a Gas6-related disease, comprising the antibody or the antibody fragment as an active ingredient, and use of the antibody or the antibody fragment for the production of a therapeutic agent or a diagnostic agent for a Gas6-related disease.Type: ApplicationFiled: October 20, 2015Publication date: November 29, 2018Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Yuko UBE, Tsuyoshi YAMADA, Yuji YAMAZAKI, Kaname KIMURA, Akiko HARIGUCHI, Shinya OGAWA
-
Patent number: 8969040Abstract: The present invention provides an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the antibody fragment, a DNA encoding the antibody or the antibody fragment, a vector comprising the DNA, a transformant obtained by introduction of the vector, a method for preparing the antibody or the antibody fragment using the hybridoma or the transformant, and a therapeutic agent comprising the antibody or the antibody fragment as an active ingredient. Further, the present invention provides a pharmaceutical composition comprising the antibody or the antibody fragment as an active ingredient for the treatment of anemia such as renal anemia, cancer anemia or the like, and a method for treating anemia such as renal anemia, cancer anemia or the like using the same.Type: GrantFiled: July 2, 2013Date of Patent: March 3, 2015Assignee: Kyowa Hakko Kirin Co., LtdInventors: Kiyoshi Shimizu, Yuji Yamazaki, Tsuguo Kubota, Kaname Kimura
-
Publication number: 20140214786Abstract: An Internet search apparatus includes a current location detection unit configured to detect a current location, an administrative district name acquisition unit configured to acquire a name of an administrative district to which the current location belongs, and an information search unit configured to perform an Internet search and display a search result in the form of a list such that a web page that does not include the administrative district name is excluded.Type: ApplicationFiled: December 4, 2013Publication date: July 31, 2014Applicant: Alpine Electronics, Inc.Inventors: Yusuke Sato, Kaname Kimura
-
Publication number: 20140056902Abstract: The present invention provides an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the antibody fragment, a DNA encoding the antibody or the antibody fragment, a vector comprising the DNA, a transformant obtained by introduction of the vector, a method for preparing the antibody or the antibody fragment using the hybridoma or the transformant, and a therapeutic agent comprising the antibody or the antibody fragment as an active ingredient. Further, the present invention provides a pharmaceutical composition comprising the antibody or the antibody fragment as an active ingredient for the treatment of anemia such as renal anemia, cancer anemia or the like, and a method for treating anemia such as renal anemia, cancer anemia or the like using the same.Type: ApplicationFiled: July 2, 2013Publication date: February 27, 2014Applicant: Kyowa Hakko Kirin Co., LtdInventors: Kiyoshi SHIMIZU, Yuji YAMAZAKI, Tsuguo KUBOTA, Kaname KIMURA
-
Publication number: 20090312313Abstract: The present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein X represents CH or N; Z represents —O—, —NH— or —C(?O)—; R and R? represent a hydrogen atom, hydroxyl, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkoxy, amino, aminocarbonyl, or an optionally substituted heterocyclic group; and A represents an optionally substituted specific carbocyclic or heterocyclic group. The compounds according to the present invention have excellent TGF? inhibitory activity.Type: ApplicationFiled: May 26, 2009Publication date: December 17, 2009Applicant: KIRIN BEER KABUSHIKI KAISHAInventors: Kiyoshi Shimizu, Toshiyuki Shimizu, Kaname Kimura, Kazuki Kawakami, Masayoshi Nakoji
-
Patent number: 7560558Abstract: The present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein X represents CH or N; Z represents —O—, —NH— or —C(?O)—; R and R? represent a hydrogen atom, hydroxyl, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkoxy, amino, aminocarbonyl, or an optionally substituted heterocyclic group; and A represents an optionally substituted specific carbocyclic or heterocyclic group. The compounds according to the present invention have excellent TGF? inhibitory activity.Type: GrantFiled: August 22, 2003Date of Patent: July 14, 2009Assignee: Kirin Beer Kabushiki KaishaInventors: Kiyoshi Shimizu, Toshiyuki Shimizu, Kaname Kimura, Kazuki Kawakami, Masayoshi Nakoji
-
Publication number: 20060111375Abstract: The present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein X represents CH or N; Z represents —O—, —NH— or —C(?O)—; R and R? represent a hydrogen atom, hydroxyl, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkoxy, amino, aminocarbonyl, or an optionally substituted heterocyclic group; and A represents an optionally substituted specific carbocyclic or heterocyclic group. The compounds according to the present invention have excellent TGF? inhibitory activity.Type: ApplicationFiled: August 22, 2003Publication date: May 25, 2006Applicant: Kirin Beer Kabushiki KaishaInventors: Kiyoshi Shimizu, Toshiyuki Shimizu, Kaname Kimura, Kazuki Kawakami, Masayoshi Nakoji